TransCode Therapeutics, Inc.

RNAZ · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$17-$19-$18-$7
Dep. & Amort.$1$1$0$0
Deferred Tax$0$0$0$1
Stock-Based Comp.$2$1$0$0
Change in WC-$0-$1$1$0
Other Non-Cash$2$0$0$0
Operating Cash Flow-$13-$18-$16-$5
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$0-$0-$0-$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$16$16$0$26
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0-$1
Financing Cash Flow$16$16$0$26
Forex Effect$0$0$0$0
Net Chg. in Cash$3-$2-$16$20
Supplemental Information
Beg. Cash$3$5$21$1
End Cash$6$3$5$21
Free Cash Flow-$13-$18-$16-$6
TransCode Therapeutics, Inc. (RNAZ) Financial Statements & Key Stats | AlphaPilot